Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Journal for Immunotherapy of Cancer|February 29, 2020
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysisFlora Mulkey, Marc R Theoret, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple MyelomaKavita Natrajan, Megha Kaushal, Bindu George, et al.
Clinical Pharmacology and Therapeutics|April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: MelanomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell LymphomaPoornima Sharma, Yvette L Kasamon, Xue Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve BetterKristin M Wessel, Nicole Drezner, Stacy S Shord, et al.
Cancer Research|July 16, 2010
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali, Zhiya Yu, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple MyelomaPoornima Sharma, Xue Lin, Zhenzhen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple MyelomaPoornima Sharma, Bindu Kanapuru, Bindu George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|February 29, 2020
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysisFlora Mulkey, Marc R Theoret, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple MyelomaKavita Natrajan, Megha Kaushal, Bindu George, et al.
Clinical Pharmacology and Therapeutics|April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: MelanomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell LymphomaPoornima Sharma, Yvette L Kasamon, Xue Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve BetterKristin M Wessel, Nicole Drezner, Stacy S Shord, et al.
Cancer Research|July 16, 2010
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali, Zhiya Yu, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple MyelomaPoornima Sharma, Xue Lin, Zhenzhen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple MyelomaPoornima Sharma, Bindu Kanapuru, Bindu George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
Pageof 11